Are Aspergillus spp. driving COPD exacerbations?
- PMID: 39609042
- DOI: 10.1183/13993003.01976-2024
Are Aspergillus spp. driving COPD exacerbations?
Conflict of interest statement
Conflict of interest: M. Bertuzzi has no potential conflicts of interest to disclose. D.W. Denning has founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company, and share options in TFF Pharma; acts or has recently acted as a consultant to Pulmocide, Biosergen, TFF Pharmaceuticals, Rostra Therapeutics, Pfizer, Mundipharma, Lifemine and Cipla; chairs a data review committee for Pulmocide and Biosergen; has been paid for talks on behalf of Hikma, Gilead, Avni, Pfizer and Knight in the past 3 years; and has contributed to multiple guidelines related to aspergillosis and fungal diagnostics.
Comment on
-
Residential exposure to Aspergillus spp. is associated with exacerbations in COPD.Eur Respir J. 2024 Nov 28;64(5):2400907. doi: 10.1183/13993003.00907-2024. Print 2024 Nov. Eur Respir J. 2024. PMID: 39362665 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous